Ad
ADXS Stock - Advaxis Stock Trading
About | Advaxis (OTCMKTS:ADXS)
Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.
Quote | Advaxis (OTCMKTS:ADXS)
| Last: | $0.0895 |
|---|---|
| Change Percent: | -72.22% |
| Open: | $0.0465 |
| Close: | $0.0895 |
| High: | $0.0895 |
| Low: | $0.0465 |
| Volume: | 3,931 |
| Last Trade Date Time: | 10/02/2024 03:00:00 am |
News | Advaxis (OTCMKTS:ADXS)
-
2024-06-27 14:14:36 ET Summary Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-d...
-
2024-05-09 16:18:02 ET More on Advaxis Financial information for Advaxis Read the full article on Seeking Alpha For further details see: Ayala Pharmaceuticals files Form 15 to voluntarily deregister and suspend reporting obligations
Message Board Posts | Advaxis (OTCMKTS:ADXS)
| Subject | By | Source | When |
|---|---|---|---|
| The only safe haven for $$$$ these days | hdwrsft | investorshub | 03/22/2023 5:15:04 PM |
| What a turd. CEO Ken is running this | Ryguy008 | investorshub | 03/20/2023 2:35:37 PM |
| Another massive bank shockingly failed. One day it's | hdwrsft | investorshub | 03/12/2023 6:03:14 AM |
| Just think, in just another 7 years, and | hdwrsft | investorshub | 02/14/2023 2:26:10 PM |
| If there is any justice in this universe, | HereToFightScams | investorshub | 01/11/2023 4:23:53 AM |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) ...
-
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
-
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...
Important Investor News Alert (OTC: AABB)
-
LAS VEGAS, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) is pleased to announce that the development of the new next generation AABB Wallet App is nearing completion. The AABB Wallet development team, led by the Koinfold Cr...